Pasar al contenido principal

EL FACTOR DE TRANSCRIPCION NRF2 EN LA PATOFISIOLOGIA DE LA ENFERMEDAD DE ALZHEIMER

PID2019-110061RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 22
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

An inhibitor of interaction between the transcription factor NRF2 and the E3 ubiquitin ligase adapter β-TrCP delivers anti-inflammatory responses in mouse liver

  • Fernández-Ginés, Raquel
  • Encinar, José Antonio
  • Hayes, John D.
  • Oliva Miguel, Baldomero
  • Rodríguez-Franco, Maria Isabel
  • Rojo, Ana I.
  • Cuadrado, Antonio
It is widely accepted that activating the transcription factor NRF2 will blast the physiological anti-inflammatory mechanisms, which will help combat pathologic inflammation. Much effort is being put in inhibiting the main NRF2 repressor, KEAP1, with either electrophilic small molecules or disrupters of the KEAP1/NRF2 interaction. However, targeting β-TrCP, the non-canonical repressor of NRF2, has not been considered yet. After in silico screening of ∼1 million compounds, we now describe a novel small molecule, PHAR, that selectively inhibits the interaction between β-TrCP and the phosphodegron in transcription factor NRF2. PHAR upregulates NRF2-target genes such as Hmox1, Nqo1, Gclc, Gclm and Aox1, in a KEAP1-independent, but β-TrCP dependent manner, breaks the β-TrCP/NRF2 interaction in the cell nucleus, and inhibits the β-TrCP-mediated in vitro ubiquitination of NRF2. PHAR attenuates hydrogen peroxide induced oxidative stress and, in lipopolysaccharide-treated macrophages, it downregulates the expression of inflammatory genes Il1b, Il6, Cox2, Nos2. In mice, PHAR selectively targets the liver and greatly attenuates LPS-induced liver inflammation as indicated by a reduction in the gene expression of the inflammatory cytokines Il1b, TNf, and Il6, and in F4/80-stained liver resident macrophages. Thus, PHAR offers a still unexplored alternative to current NRF2 activators by acting as a β-TrCP/NRF2 interaction inhibitor that may have a therapeutic value against undesirable inflammation., This research was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) (grants PID2019-110061RB-I00, PID2021-122650OB-I00, and PDC2021-121421-I00) and The Autonomous Community of Madrid (grant B2017/BMD-3827). RFG enjoyed FPI contract of MINECO (FPI-2017). The Spanish Ministry of Economy and Competitiveness (MINECO, Project RTI2018-096724-B-C21) and the Generalitat Valenciana (PROMETEO/2021/059) supported the work in the Encinar laboratory.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

WIP modulates oxidative stress through NRF2/KEAP1 in glioblastoma cells

  • Escoll, Maribel
  • Lastra, Diego
  • Robledinos-Antón, Natalia
  • Wandosell, Francisco
  • Antón, Inés María
  • Cuadrado, Antonio
Due to their high metabolic rate, tumor cells produce exacerbated levels of reactive oxygen species that need to be under control. Wiskott–Aldrich syndrome protein (WASP)-interacting protein (WIP) is a scaffold protein with multiple yet poorly understood functions that participates in tumor progression and promotes cancer cell survival. However, its participation in the control of oxidative stress has not been addressed yet. We show that WIP depletion increases the levels of reactive oxygen species and reduces the levels of transcription factor NRF2, the master regulator of redox homeostasis. We found that WIP stabilizes NRF2 by restraining the activity of its main NRF2 repressor, the E3 ligase adapter KEAP1, because the overexpression of a NRF2ΔETGE mutant that is resistant to targeted proteasome degradation by KEAP1 or the knock-down of KEAP1 maintains NRF2 levels in the absence of WIP. Mechanistically, we show that the increased KEAP1 activity in WIP-depleted cells is not due to the protection of KEAP1 from autophagic degradation, but is dependent on the organization of the Actin cytoskeleton, probably through binding between KEAP1 and F-Actin. Our study provides a new role of WIP in maintaining the oxidant tolerance of cancer cells that may have therapeutic implications., This work was supported by PID2019-110061RB-I00, RTI2018-096303-B-C31 and SAF2017-82436R of the Spanish Ministry of Economy and Competiveness; and by the P_37_732/2016 grant (REDBRAIN) financed by the European Regional Development Fund, Competitiveness Operational Program 2014–2020, and Comunidad Autónoma de Madrid (grant B2017/BMD-3827). M.E. was recipient of a postdoctoral contract Juan de la Cierva; D.L. and N.R.-A. enjoied a FPU contract of MINECO., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Inflammation in Parkinson’s disease: Mechanisms and therapeutic implications

  • Pajares, Marta
  • Rojo, Ana I.
  • Manda, Gina
  • Boscá, Lisardo
  • Cuadrado, Antonio
This article belongs to the Special Issue Neuroinflammation in Neurodegenerative and Neurological Diseases., Parkinson’s disease (PD) is a common neurodegenerative disorder primarily characterized by the death of dopaminergic neurons that project from the substantia nigra pars compacta. Although the molecular bases for PD development are still little defined, extensive evidence from human samples and animal models support the involvement of inflammation in onset or progression. However, the exact trigger for this response remains unclear. Here, we provide a systematic review of the cellular mediators, i.e., microglia, astroglia and endothelial cells. We also discuss the genetic and transcriptional control of inflammation in PD and the immunomodulatory role of dopamine and reactive oxygen species. Finally, we summarize the preclinical and clinical approaches targeting neuroinflammation in PD., This work was supported by PID2019-110061RB-I00 and SAF2017-82436R of the Spanish Ministry of Economy and Competiveness; P-024-FTPGB 2018 from the Spanish “Tatiana de Guzman el Bueno Foundation” and by the P_37_732/2016 grant (REDBRAIN) financed by the European Regional Development Fund, Competitiveness Operational Program 2014–2020. Comunidad Autónoma de Madrid (grants B2017/BMD-3827, S2017-BMD-3686). MP is recipient of a contract Juan de la Cierva (MICINN)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

NRF2 as a therapeutic opportunity to impact in the molecular roadmap of ALS

  • Jiménez-Villegas, José
  • Ferraiuolo, L.
  • Mead, R. J.
  • Shaw, P. J.
  • Cuadrado, Antonio
  • Rojo, Ana I.
Amyotrophic Lateral Sclerosis (ALS) is a devastating heterogeneous disease with still no convincing therapy. To identify the most strategically significant hallmarks for therapeutic intervention, we have performed a comprehensive transcriptomics analysis of dysregulated pathways, comparing datasets from ALS patients and healthy donors. We have identified crucial alterations in RNA metabolism, intracellular transport, vascular system, redox homeostasis, proteostasis and inflammatory responses. Interestingly, the transcription factor NRF2 (nuclear factor (erythroid-derived 2)-like 2) has significant effects in modulating these pathways. NRF2 has been classically considered as the master regulator of the antioxidant cellular response, although it is currently considered as a key component of the transduction machinery to maintain coordinated control of protein quality, inflammation, and redox homeostasis. Herein, we will summarize the data from NRF2 activators in ALS pre-clinical models as well as those that are being studied in clinical trials. As we will discuss, NRF2 is a promising target to build a coordinated transcriptional response to motor neuron injury, highlighting its therapeutic potential to combat ALS., This work was supported by a COEN-2018-Pathfinder phase III grant financed by the Medical Research Council Network of Centres of Excellence in Neurodegeneration (MR/S004920/1). AC and AIR are supported by PID2019-110061RB-I00 of the Spanish Ministry of Economy and Competiveness and P-024-FTPGB 2018 from Foundation Tatiana de Guzman el Bueno. PJS is supported as an NIHR Senior Investigator (NF-SI-0617-10077) and by the Sheffield NIHR Biomedical Research Centre (brc-1215-20017). JJV is holder of a master's degree fellowship (“Ayudas para el fomento de la Investigación en Estudios de Máster-UAM 2020”) funded by the Autonomous University of Madrid.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

α-Synuclein Induces the GSK-3-Mediated Phosphorylation and Degradation of NURR1 and Loss of Dopaminergic Hallmarks

  • García-Yagüe, Ángel Juan
  • Lastres-Becker, Isabel
  • Stefanis, Leonidas
  • Vassilatis, Demetrios K.
  • Cuadrado, Antonio
© The Author(s) 2021., In Parkinson’s disease, the dysfunction of the dopaminergic nigrostriatal tract involves the loss of function of dopaminergic neurons of the substantia nigra pars compacta followed by death of these neurons. The functional recovery of these neurons requires a deep knowledge of the molecules that maintain the dopaminergic phenotype during adulthood and the mechanisms that subvert their activity. Previous studies have shown that transcription factor NURR1, involved in differentiation and maintenance of the dopaminergic phenotype, is downregulated by α-synuclein (α-SYN). In this study, we provide a mechanistic explanation to this finding by connecting α-SYN-induced activation of glycogen synthase kinase-3 (GSK-3) with NURR1 phosphorylation followed by proteasomal degradation. The use of sequential deletion mutants and single point mutants of NURR1 allowed the identification of a domain comprising amino acids 123-PSSPPTPSTPS-134 that is targeted by GSK-3 and leads to subsequent ubiquitination and proteasome degradation. This study provides a detailed analysis of the regulation of NURR1 stability by phosphorylation in synucleinopathies such as Parkinson’s disease., This study was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) (grant PID2019-110061RB-I00 for A.C and PID2019-105600RB-I00 for I.L.B.) and The Autonomous Community of Madrid (grant B2017/ BMD-3827 for A.C. and B2017/BMD-3813 for I.L.B.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel Series of Dual NRF2 Inducers and Selective MAO-B Inhibitors for the Treatment of Parkinson's Disease

  • Duarte, Pablo
  • Michalska, Patrycja
  • Crisman, Enrique
  • Cuadrado, Antonio
  • León, Rafael
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease. It is characterized by a complex network of physiopathological events where oxidative stress plays a central role among other factors such as neuroinflammation and protein homeostasis. Nuclear factor-erythroid 2 p45-related factor 2 (NRF2) has a multitarget profile itself as it controls a plethora of cellular processes involved in the progression of the disease. In this line, we designed a novel family of 2-(1H-indol-3-yl)ethan-1-amine derivatives as NRF2 inducers with complementary activities. Novel compounds are based on melatonin scaffold and include, among other properties, selective monoamine oxidase B (MAO-B) inhibition activity. Novel multitarget compounds exhibited NRF2 induction activity and MAO-B selective inhibition, combined with anti-inflammatory, antioxidant, and blood–brain barrier permeation properties. Furthermore, they exert neuroprotective properties against oxidative stress toxicity in PD-related in vitro. Hit compound 14 reduced oxidative stress markers and exerted neuroprotection in rat striatal slices exposed to 6-hydroxydopamine or rotenone. In conclusion, we developed a promising family of dual NRF2 inducers and selective MAO-B inhibitors that could serve as a novel therapeutic strategy for PD treatmen, This research was funded by the IS Carlos III co-financed by the European Regional Development funds (FEDER) (grant PI17/01700 to RL) by the Spanish Ministry of Economy and Competitiveness (MINECO) (grant PID2019-110061RB-I00 to A.C.) and Comunidad Autónoma de Madrid (grant B2017/BMD-3827, RL). The APC was not funde
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

An inhibitor of interaction between the transcription factor NRF2 and the E3 ubiquitin ligase adapter ß-TrCP delivers anti-inflammatory responses in mouse liver

  • Fernández-Ginés, Raquel
  • Encinar, José Antonio
  • Hayes, J. D.
  • Oliva, B.
  • Estrada-Valencia, M.
  • Rodríguez-Franco, María Isabel
  • Rojas, A. I.
  • Cuadrado, Antonio
It is widely accepted that activating the transcription factor NRF2 will blast the physiological anti-inflammatory mechanisms, which will help combat pathologic inflammation. Much effort is being put in inhibiting the main NRF2 repressor, KEAP1, with either electrophilic small molecules or disrupters of the KEAP1/NRF2 interaction. However, targeting ß-TrCP, the non-canonical repressor of NRF2, has not been considered yet. After in silico screening of ~1 million compounds, we now describe a novel small molecule, PHAR, that selectively inhibits the interaction between ß-TrCP and the phosphodegron in transcription factor NRF2. PHAR upregulates NRF2-target genes such as Hmox1, Nqo1, Gclc, Gclm and Aox1, in a KEAP1-independent, but ß-TrCP dependent manner, breaks the ß-TrCP/NRF2 interaction in the cell nucleus, and inhibits the ß-TrCP-mediated in vitro ubiquitination of NRF2. PHAR attenuates hydrogen peroxide induced oxidative stress and, in lipopolysaccharide-treated macrophages, it downregulates the expression of inflammatory genes Il1b, Il6, Cox2, Nos2. In mice, PHAR selectively targets the liver and greatly attenuates LPS-induced liver inflammation as indicated by a reduction in the gene expression of the inflammatory cytokines Il1b, TNf, and Il6, and in F4/80-stained liver resident macrophages. Thus, PHAR offers a still unexplored alternative to current NRF2 activators by acting as a ß-TrCP/NRF2 interaction inhibitor that may have a therapeutic value against undesirable inflammation., This research was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) (grants PID2019-110061RB-I00, PID2021- 122650OB-I00, and PDC2021-121421-I00) and The Autonomous Com- munity of Madrid (grant B2017/BMD-3827). RFG enjoyed FPI contract of MINECO (FPI-2017). The Spanish Ministry of Economy and Competitiveness (MINECO, Project RTI2018-096724-B-C21) and the Generalitat Valenciana (PROMETEO/2021/059) supported the work in the Encinar laboratory.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Brain-protective mechanisms of transcription factor NRF2: toward a common strategy for neurodegenerative diseases

  • Cuadrado, Antonio
Neurodegenerative diseases are characterized by the loss of homeostatic functions that control redox and energy metabolism, neuroinflammation, and proteostasis. The transcription factor nuclear factor erythroid 2–related factor 2 (NRF2) is a master controller of these functions, and its overall activity is compromised during aging and in these diseases. However, NRF2 can be activated pharmacologically and is now being considered a common therapeutic target. Many gaps still exist in our knowledge of the specific role that NRF2 plays in specialized brain cell functions or how these cells respond to the hallmarks of these diseases. This review discusses the relevance of NRF2 to several hallmark features of neurodegenerative diseases and the current status of pharmacological activators that might pass through the blood-brain barrier and provide a disease-modifying effect., This study was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) (grant PID2019-110061RB-I00), the Autonomous Community of Madrid (grant B2017/BMD-3827), and the European Regional Development Fund Competitiveness Operational Program 2014–2020 (the REDBRAIN project, ID P_37_732). The author is the main proponent of COST Action 20121, BenBedPhar, on Bench to Bedside Transition for Pharmacological Regulation of NRF2 in Noncommunicable Diseases.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Protective actions of nuclear factor erythroid 2-related factor 2 (NRF2) and downstream pathways against environmental stressors

  • Bayo, Mª Teresa
  • Frenis, Katie
  • Hahad, Omar
  • Steven, Sebastian
  • Cohen, Guy
  • Cuadrado, Antonio
  • Münzel, Thomas
  • Daiber, Andreas
Environmental risk factors, including noise, air pollution, chemical agents, ultraviolet radiation (UVR) and mental stress have a considerable impact on human health. Oxidative stress and inflammation are key players in molecular pathomechanisms of environmental pollution and risk factors. In this review, we delineate the impact of environmental risk factors and the protective actions of the nuclear factor erythroid 2-related factor 2 (NRF2) in connection to oxidative stress and inflammation. We focus on well-established studies that demonstrate the protective actions of NRF2 and its downstream pathways against different environmental stressors. State-of-the-art mechanistic considerations on NRF2 signaling are discussed in detail, e.g. classical concepts like KEAP1 oxidation/electrophilic modification, NRF2 ubiquitination and degradation. Specific focus is also laid on NRF2-dependent heme oxygenase-1 induction with detailed presentation of the protective down-stream pathways of heme oxygenase-1, including interaction with BACH1 system. The significant impact of all environmental stressors on the circadian rhythm and the interactions of NRF2 with the circadian clock will also be considered here. A broad range of NRF2 activators is discussed in relation to environmental stressor-induced health side effects, thereby suggesting promising new mitigation strategies (e.g. by nutraceuticals) to fight the negative effects of the environment on our health., S.Ste. holds an excellence grant and a research grant related to noise/hypertension from the Else Kroner ¨ Fresenius Foundation. T.M. is PI of the DZHK (German Center for Cardiovascular Research), Partner Site Rhine-Main, Mainz, Germany. S.Ste., T.M. and A.D. were supported by vascular biology research grants from the Boehringer Ingelheim Foundation for the collaborative research group ‘Novel and neglected cardiovascular risk factors: Molecular mechanisms and therapeutics’. A.C. holds grant PID2019-110061RB-I00 from MICINN. M.T.B.J. and K.F. hold stipends from the TransMed PhD Program of the University Medical Center Mainz funded by the Boehringer Ingelheim Foundation.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Overlooked and valuable facts to know in the NRF2/KEAP1 field

  • Kopacz, Aleksandra
  • Rojo, Ana I.
  • Patibandla, Chinmai
  • Lastra, Diego
  • Piechota-Polanczyk, Aleksandra
  • Kloska, Damian
  • Jozkowicz, Alicja
  • Sutherland, Calum
  • Cuadrado, Antonio
  • Grochot-Przeczek, Anna
NRF2 (nuclear factor erythroid 2-related factor 2) is a critical regulator of the cellular stress response. It is a transcription factor that controls the expression of hundreds of genes. We will soon celebrate the thirtieth anniversary of its discovery [1]. Over the years, NRF2 and its repressor KEAP1 have become the subject of intensive research, ranging from the detailed molecular mechanisms of their activity to clinical perspectives and generating over a dozen thousand publications. This review intends to draw the attention of researchers to essential issues in the NRF2/KEAP1 field, highlighting the overlooked facts and clarifying potential misconceptions., This research was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) (grants PID2019-110061RB-I00, and PDC2021-121421-I00) and The Autonomous Community of Madrid (grant B2017/BMD-3827). FLM enjoyed FPI contract of MINECO (FPI-2017). The National Science Centre supported this work with grants Sonata Bis No. 2016/22/E/NZ3/00405 (AGP), Opus No. 2021/43/B/NZ4/02130 (AGP), and Sonata No. 2018/31/D/NZ4/00077 (APP). AK is supported by L'Oreal for Women in Science and START Scholarship from Foundation for Polish Science. CP and CS are supported by Diabetes UK award 20/0006178.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The current status and future prospects for therapeutic targeting of KEAP1-NRF2 and β-TrCP-NRF2 interactions in cancer chemoresistance

  • Srivastava, Rohini
  • Fernández-Ginés, Raquel
  • Encinar, José Antonio
  • Cuadrado, Antonio
  • Wells, Geoffrey
Drug resistance is one of the biggest challenges in cancer treatment and limits the potential to cure patients. In many tumors, sustained activation of the protein NRF2 makes tumor cells resistant to chemo- and radiotherapy. Thus, blocking inappropriate NRF2 activity in cancers has been shown to reduce resistance in models of the disease. There is a growing scientific interest in NRF2 inhibitors. However, the compounds developed so far are not target-specific and are associated with a high degree of toxicity, hampering clinical applications. Compounds that can enhance the binding of NRF2 to its ubiquitination-facilitating regulator proteins, either KEAP1 or β-TrCP, have the potential to increase NRF2 degradation and may be of value as potential chemosensitising agents in cancer treatment. Approaches based on molecular glue-type mechanisms, in which ligands stabilise a ternary complex between a protein and its binding partner have shown to enhance β-catenin degradation by stabilising its interaction with β-TrCP. This strategy could be applied to rationally discover degradative β-TrCP-NRF2 and KEAP1-NRF2 protein-protein interaction enhancers. We are proposing a novel approach to selectively suppress NRF2 activity in tumors. It is based on recent methodology and has the potential to be a promising new addition to the arsenal of anticancer agents., This article is based upon work from COST Action CA20121, supported by the European Cooperation in Science and Technology (www.cost.eu) (https://benbedphar.org/about-benbedphar/). This research was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) (grants PID2019-110061RB-I00) and Generalitat Valenciana (PROMETEO/2021/059) and UCL School of Pharmacy.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dipeptide repeat pathology in C9orf72-ALS is associated with redox, mitochondrial and NRF2 pathway imbalance

  • Jiménez-Villegas, José
  • Kirby, Janine
  • Mata, Ana M.
  • Cadenas, Susana
  • Turner, Martin R.
  • Malaspina, Andrea
  • Shaw, Pamela J.
  • Cuadrado, Antonio
  • Rojo, Ana I.
The hexanucleotide expansion of the C9orf72 gene is found in 40% of familial amyotrophic lateral sclerosis (ALS) patients. This genetic alteration has been connected with impaired management of reactive oxygen species. In this study, we conducted targeted transcriptional profiling in leukocytes from C9orf72 patients and control subjects by examining the mRNA levels of 84 redox-related genes. The expression of ten redox genes was altered in samples from C9orf72 ALS patients compared to healthy controls. Considering that Nuclear factor erythroid 2-Related Factor 2 (NRF2) modulates the expression of a wide range of redox genes, we further investigated its status on an in vitro model of dipeptide repeat (DPR) toxicity. This model mimics the gain of function, toxic mechanisms attributed to C9orf72 pathology. We found that exposure to DPRs increased superoxide levels and reduced mitochondrial potential as well as cell survival. Importantly, cells overexpressing DPRs exhibited reduced protein levels of NRF2 and its target genes upon inhibition of the proteasome or its canonical repressor, the E3 ligase adapter KEAP1. However, NRF2 activation was sufficient to recover cell viability and redox homeostasis. This study identifies NRF2 as a putative target in precision medicine for the therapy of ALS patients harboring C9orf72 expansion repeats., This work was supported by the SAF2019-110061RB-100 grant from the Spanish Ministry of Economy and Competitiveness; P-024-FTPGB 2018 from the Spanish Foundation named “Tatiana de Guzman el Bueno”, COEN-2018-Pathfinder phase III financed by the Network of Centers of Excellence in Neurodegeneration including the UK Medical Research Council and PI19/01030 financed by the Spanish “Instituto de Salud Carlos III”. J.J.V. hold an FPU PhD fellowship from the Spanish Ministry of Universities (FPU20/03326) and was a holder of a master’s degree fellowship (“Ayudas para el fomento de la Investigación en Estudios de Máster-UAM 2020”) funded by the Autonomous University of Madrid. This research was also supported by the Motor Neurone Disease Association (AMBRoSIA 972-797 and NECTAR 974-797 awards) and by the NIHR Sheffield Biomedical Research Centre (JS-BRC-1215-20017). This article is based upon work from COST Action CA20121, supported by COST (European Cooperation in Science and Technology).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

KEAP1-NRF2 protein–protein interaction inhibitors: Design, pharmacological properties and therapeutic potential

  • Crisman, Enrique
  • Duarte, Pablo
  • Dauden, Esteban
  • Cuadrado, Antonio
  • Rodríguez-Franco, María Isabel
  • López, Manuela G.
  • León, Rafael
The transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) is considered the master regulator of the phase II antioxidant response. It controls a plethora of cytoprotective genes related to oxidative stress, inflammation, and protein homeostasis, among other processes. Activation of these pathways has been described in numerous pathologies including cancer, cardiovascular, respiratory, renal, digestive, metabolic, autoimmune, and neurodegenerative diseases. Considering the increasing interest of discovering novel NRF2 activators due to its clinical application, initial efforts were devoted to the development of electrophilic drugs able to induce NRF2 nuclear accumulation by targeting its natural repressor protein Kelch-like ECH-associated protein 1 (KEAP1) through covalent modifications on cysteine residues. However, off-target effects of these drugs prompted the development of an innovative strategy, the search of KEAP1-NRF2 protein–protein interaction (PPI) inhibitors. These innovative activators are proposed to target NRF2 in a more selective way, leading to potentially improved drugs with the application for a variety of diseases that are currently under investigation. In this review, we summarize known KEAP1-NRF2 PPI inhibitors to date and the bases of their design highlighting the most important features of their respective interactions. We also discuss the preclinical pharmacological properties described for the most promising compounds., Enrique Crisman is the recipient of a PFIS fellowship of ISCIII. Pablo Duarte is the recipient of an FPU fellowship of the Spanish Ministry of education. Authors gratefully acknowledge funding from IS Carlos III, Comunidad de Madrid, and Spanish Research Agency. We thank Fundación Teófilo Hernando for its continued support. All schemes were created with Biorender.com. IS Carlos III cofinanced by the European Regional Development funds (FEDER) grant number PI17/01700. General Council for Research and Innovation of the Community of Madrid and European Structural Funds (grant B2017/BMD‐3827 NRF24ADCM. Spanish Ministry of Science, Innovation and Universities (grants PID2021‐123481OB‐I00, PID2021‐122650OB‐I00, PID2021‐125986OB‐I00, PDC2021‐121421‐I00, and PID2019‐110061RB‐I00). The authors have no financial support to disclose., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mechanisms of NURR1 Regulation: Consequences for Its Biological Activity and Involvement in Pathology

  • García-Yagüe, Ángel Juan
  • Cuadrado, Antonio
NURR1 (Nuclear receptor-related 1 protein or NR4A2) is a nuclear protein receptor transcription factor with an essential role in the development, regulation, and maintenance of dopaminergic neurons and mediates the response to stressful stimuli during the perinatal period in mammalian brain development. The dysregulation of NURR1 activity may play a role in various diseases, including the onset and progression of neurodegenerative diseases, and several other pathologies. NURR1 is regulated by multiple mechanisms, among which phosphorylation by kinases or SUMOylation are the best characterized. Both post-translational modifications can regulate the activity of NURR1, affecting its stability and transcriptional activity. Other non-post-translational regulatory mechanisms include changes in its subcellular distribution or interaction with other protein partners by heterodimerization, also affecting its transcription activity. Here, we summarize the currently known regulatory mechanisms of NURR1 and provide a brief overview of its participation in pathological alterations., This study was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) (grant PID2019-110061RB-I00 for A.C.) and The Autonomous Community of Madrid (grant B2017/BMD-3827 for A.C.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

O-GlcNAcylation enhances CPS1 catalytic efficiency for ammonia and promotes ureagenesis

  • Soria, Leandro R.
  • Makris, Georgios
  • D’Alessio, Alfonso M.
  • De Angelis, Angela
  • Boffa, Iolanda
  • Pravata, Veronica M.
  • Rüfenacht, Véronique
  • Attanasio, Sergio
  • Nusco, Edoardo
  • Arena, Paola
  • Ferenbach, Andrew T.
  • Paris, Debora
  • Cuomo, Paola
  • Motta, Andrea
  • Nitzahn, Matthew
  • Lipshutz, Gerald S.
  • Martínez-Pizarro, Ainhoa
  • Richard, Eva
  • Desviat, Lourdes R.
  • Häberle, Johannes
  • van Aalten, Daan M. F.
  • Brunetti-Pierri, Nicola
Life-threatening hyperammonemia occurs in both inherited and acquired liver diseases affecting ureagenesis, the main pathway for detoxification of neurotoxic ammonia in mammals. Protein O-GlcNAcylation is a reversible and nutrient-sensitive post-translational modification using as substrate UDP-GlcNAc, the end-product of hexosamine biosynthesis pathway. Here we show that increased liver UDP-GlcNAc during hyperammonemia increases protein O-GlcNAcylation and enhances ureagenesis. Mechanistically, O-GlcNAcylation on specific threonine residues increased the catalytic efficiency for ammonia of carbamoyl phosphate synthetase 1 (CPS1), the rate-limiting enzyme in ureagenesis. Pharmacological inhibition of O-GlcNAcase, the enzyme removing O-GlcNAc from proteins, resulted in clinically relevant reductions of systemic ammonia in both genetic (hypomorphic mouse model of propionic acidemia) and acquired (thioacetamide-induced acute liver failure) mouse models of liver diseases. In conclusion, by fine-tuned control of ammonia entry into ureagenesis, hepatic O-GlcNAcylation of CPS1 increases ammonia detoxification and is a novel target for therapy of hyperammonemia in both genetic and acquired diseases., This work was supported by grants of Fondazione Telethon Italy (to N.B.‐P.), MIUR (PRIN2017 to N.B.‐P.), of the Swiss National Science Foundation (grant 320030_176088 to J.H.), of the US National Institutes of Health grants (R21NS091654 and R01NS100979 both to G.S.L.), of the Spanish Ministry of Science and Innovation (PID2019-105344RB-I00/AEI/10.13039/501100011033 to L.R.D. and E.R.), and by a Wellcome Trust Investigator Award (110061 to D.M.F.v.A.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Specific targeting of the NRF2/β-TrCP axis promotes beneficial effects in NASH

  • Fernández-Ginés, Raquel
  • Encinar, José Antonio
  • Escoll, Maribel
  • Carnicero-Senabre, Daniel
  • Jiménez-Villegas, José
  • García-Yagüe, Ángel Juan
  • González-Rodríguez, Águeda
  • García-Martínez, Irma
  • Valverde, Ángela M.
  • Rojo, Ana I.
  • Cuadrado, Antonio
Non-alcoholic steatohepatitis (NASH) is a common chronic liver disease that compromises liver function, for which there is not a specifically approved medicine. Recent research has identified transcription factor NRF2 as a potential therapeutic target. However, current NRF2 activators, designed to inhibit its repressor KEAP1, exhibit unwanted side effects. Alternatively, we previously introduced PHAR, a protein-protein interaction inhibitor of NRF2/β-TrCP, which induces a mild NRF2 activation and selectively activates NRF2 in the liver, close to normal physiological levels. Herein, we assessed the effect of PHAR in protection against NASH and its progression to fibrosis. We conducted experiments to demonstrate that PHAR effectively activated NRF2 in hepatocytes, Kupffer cells, and stellate cells. Then, we used the STAM mouse model of NASH, based on partial damage of endocrine pancreas and insulin secretion impairment, followed by a high fat diet. Non-invasive analysis using MRI revealed that PHAR protects against liver fat accumulation. Moreover, PHAR attenuated key markers of NASH progression, including liver steatosis, hepatocellular ballooning, inflammation, and fibrosis. Notably, transcriptomic data indicate that PHAR led to upregulation of 3 anti-fibrotic genes (Plg, Serpina1a, and Bmp7) and downregulation of 6 pro-fibrotic (including Acta2 and Col3a1), 11 extracellular matrix remodeling, and 8 inflammatory genes. Overall, our study suggests that the mild activation of NRF2 via the protein-protein interaction inhibitor PHAR holds promise as a strategy for addressing NASH and its progression to liver fibrosis., This research was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) (grants PID2019-110061RB-I00, PID-2021-122766OB-100 and PDC2021-121421-I00, PDC2022-133765-I00, MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe” by the European Union.), CIBERdem and CIBERned (ISCIII), and The Autonomous Community of Madrid (grant P2022/BMD-7230). RFG enjoyed a FPI contract of MINECO (FPI-2017). DCS is a holder of a FPI contract of MICINN (Ministry of Science and Innovation, FPI-2020, PRE2020-091886). JJV is holder of a FPU contract of MIU (Ministry of Universities, FPU2020, FPU20/03326)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Role of the transcription factor NRF2 in maintaining the integrity of the Blood-Brain Barrier

  • Cazalla, Eduardo
  • Cuadrado, Antonio
  • García-Yagüe, Ángel Juan
[Background]: The Blood-Brain Barrier (BBB) is a complex and dynamic interface that regulates the exchange of molecules and cells between the blood and the central nervous system. It undergoes structural and functional throughout oxidative stress and inflammation, which may compromise its integrity and contribute to the pathogenesis of neurodegenerative diseases., [Main body]: Maintaining BBB integrity is of utmost importance in preventing a wide range of neurological disorders. NRF2 is the main transcription factor that regulates cellular redox balance and inflammation-related gene expression. It has also demonstrated a potential role in regulating tight junction integrity and contributing to the inhibition of ECM remodeling, by reducing the expression of several metalloprotease family members involved in maintaining BBB function. Overall, we review current insights on the role of NRF2 in addressing protection against the effects of BBB dysfunction, discuss its involvement in BBB maintenance in different neuropathological diseases, as well as, some of its potential activators that have been used in vitro and in vivo animal models for preventing barrier dysfunction., [Conclusions]: Thus, emerging evidence suggests that upregulation of NRF2 and its target genes could suppress oxidative stress, and neuroinflammation, restore BBB integrity, and increase its protection., This research was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) (grands PDC2021-121421-I00, PDC2022-1337665-I00, PID2022-141786OB-I00 and PID2019-110061RB-I00). The Autonomous Community of Madrid (grands S2017BMD-3827 and P2022_BMD-7230). EC is holder of an FPU contract of MIU (Ministry of Universities FPU2021, FPU21/02505)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Model organisms for investigating the functional involvement of NRF2 in non-communicable diseases

  • Rojo, Ana I.
  • Buttari, Brigitta
  • Cadenas, Susana
  • Carlos, Ana Rita
  • Cuadrado, Antonio
  • Falcão, Ana Sofia
  • López, Manuela G.
  • Georgiev, Milen I.
  • Grochot-Przeczek, Anna
  • Gumeni, Sentiljana
  • Jiménez-Villegas, José
  • Horbanczuk, Jarosław Olav
  • Konu, Ozlen
  • Lastres Becker, Isabel
  • Levonen, Anna-Liisa
  • Maksimova, Viktorija
  • Michaeloudes, Charalambos
  • Mihaylova, Liliya V
  • Mickael, Michel Edwar
  • Milisav, Irina
  • Miova, Biljana
  • Rada, Patricia
  • Santos, Marlene
  • Seabra, Miguel C
  • Strac, Dubravka Svob
  • Tenreiro, Sandra
  • Trougakos, Ioannis P
  • Dinkova-Kostova, Albena T
Non-communicable chronic diseases (NCDs) are most commonly characterized by age-related loss of homeostasis and/or by cumulative exposures to environmental factors, which lead to low-grade sustained generation of reactive oxygen species (ROS), chronic inflammation and metabolic imbalance. Nuclear factor erythroid 2-like 2 (NRF2) is a basic leucine-zipper transcription factor that regulates the cellular redox homeostasis. NRF2 controls the expression of more than 250 human genes that share in their regulatory regions a cis-acting enhancer termed the antioxidant response element (ARE). The products of these genes participate in numerous functions including biotransformation and redox homeostasis, lipid and iron metabolism, inflammation, proteostasis, as well as mitochondrial dynamics and energetics. Thus, it is possible that a single pharmacological NRF2 modulator might mitigate the effect of the main hallmarks of NCDs, including oxidative, proteostatic, inflammatory and/or metabolic stress. Research on model organisms has provided tremendous knowledge of the molecular mechanisms by which NRF2 affects NCDs pathogenesis. This review is a comprehensive summary of the most commonly used model organisms of NCDs in which NRF2 has been genetically or pharmacologically modulated, paving the way for drug development to combat NCDs. We discuss the validity and use of these models and identify future challenges., Research in the authors' laboratories is funded as follows: AIR and AC by the Spanish Ministry of Science, Innovation and Universities (PID2019-110061RB-I00, PID-2021-122766OB-100, PDC2021-121421-I00, PDC2022-133765-I00), CIBERNED/ISCIII (CB06/05/0010), and The Autonomous Community of Madrid (P2022/BMD-7230). MGL is funded by Spanish Ministry of Science, Innovation and Universities (PID2021-125986OB-I00, PDC2022-133809-I00) and Community of Madrid Ref. P2022/BMD-7230-CAM-22. PR is funded by Spanish Ministry of Science, Innovation and Universities (PID2023-150994OB-I00), The Autonomous Community of Madrid (P2022/BMD-7227) and CIBERDEM/ISCIII (CB07/08/0033). JJV is holder of a FPU contract of Spanish Ministry of Science, Innovation and Universities (FPU20/03326). ILB is funded by the Spanish Ministry of Science, Innovation and Universities (PID2022-137065OB-100, PCD2022-133774-100) and CIBERNED/ISCIII (CB06/05/0089). MCS, ST and ASF are funded by Fundação para a Ciência e a Tecnologia through R&D unit iNOVA4Health (UIDB/04462/2020 and UIDP/04462/2020) and LS4FUTURE Associated Laboratory (LA/P/0087/2020). ASF is holder of a post-doctoral contract from “La Caixa Foundation” (NASCENT HR22-00569). IM received research core funding by Slovenian Research Agency (P3-0019). AG received research funding from the National Science Centre grant OPUS (2021/43/B/NZ4/02130). ARC is supported by the donor Henrique Meirelles who chose to support the MATRIHEALTH Project (CC1036), Fundação para a Ciência e a Tecnologia Project (https://doi.org/10.54499/PTDC/BTM-ORG/1383/2020) and Unit Funding (https://doi.org/10.54499/UIDB/00329/2020). IPT acknowledges funding from NKUA SARG (C.S. 19067). SC is funded by the ISCIII (PI23/01846). LVM is a grant holder of a contract КП-06-КОСТ/4 of the Bulgarian National Science Fund under BG-175467353-2023-03 programme. LVM and MIG have received funding from the European Union's Horizon 2020 research and innovation programme, project PlantaSYST (SGA No 739582 under FPA No. 664620) and by the European Regional Development Fund through the Bulgarian “Science and Education for Smart Growth” Operational Programme (BG05M2OP001-1.003-001-C01) and Programme Research Innovation and Digitalisation for Smart Transformation. OK is funded by the European Union Horizon's research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679. ADK is funded by the Medical Research Council UK (MR/W023806/1), the Biotechnology and Biological Sciences Research Council UK (BB/T508111/1 and BB/X00029X/1), Tenovus Scotland (T22-08), and the Cunnigham Trust. This article is based upon work from COST Action CA20121, supported by COST (European Cooperation in Science and Technology) (www.cost.eu) (https://benbedphar.org/about-benbedphar/, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A novel β-TrCP1/NRF2 interaction inhibitor for effective anti-inflammatory therapy

  • García-Yagüe, Ángel Juan
  • Cañizares-Moscato, Lucía
  • Encinar, José Antonio
  • Cazalla, Eduardo
  • Fernández-Ginés, Raquel
  • Escoll, Maribel
  • Rojo, Ana I.
  • Cuadrado, Antonio
[Background] Non-communicable chronic diseases are characterized by low-grade inflammation and oxidative stress. Extensive research has identified the transcription factor NRF2 as a potential therapeutic target. Current NRF2 activators, designed to inhibit its repressor KEAP1, often exhibit undesirable side effects. As an alternative approach, we previously developed PHAR, a protein–protein interaction inhibitor of β-TrCP1/NRF2, which promotes NRF2 activation. Using the same in silico screening platform, we have now identified a novel compound, P10. This small molecule selectively interferes with the β-TrCP1/NRF2 interaction, leading to NRF2 stabilization and transcriptional activation of its target genes in a β-TrCP1-dependent manner, demonstrating promising effects in a liver model of acute inflammation., [Methods] After an in silico screening of ∼1 million compounds, including molecular docking analysis, ADMET evaluation, and molecular dynamics simulations, we identified and characterized a novel small molecule, P10, which inhibits β-TrCP1/NRF2 interaction. The compound was validated using luciferase reporter assays, co-immunoprecipitation, and ubiquitination experiments. The specificity of P10 was assessed by comparing NRF2 signatures in wild-type and Nrf2-null cells. The impact of NRF2 activation induced by P10 was investigated by evaluating its antioxidant and anti-inflammatory responses against tert-butyl hydroperoxide and lipopolysaccharide, respectively. Finally, wild-type and Nrf2-null mice were administered P10 intraperitoneally at a dose of 20 mg/kg daily for five consecutive days. Four hours before sacrifice, all animals received a lipopolysaccharide (LPS) injection at 10 mg/kg., [Results] P10 selectively disrupts the interaction between β-TrCP1 and NRF2, thereby inhibiting β-TrCP1-mediated ubiquitination of NRF2 and leading to the upregulation of NRF2 target genes. Additionally, P10 mitigates oxidative stress induced by tert-butyl hydroperoxide and reduces pro-inflammatory markers in an NRF2-dependent manner in macrophages treated with lipopolysaccharide. In a preclinical model of liver inflammation, P10 specifically targets the liver, significantly attenuating lipopolysaccharide-induced inflammation through the activation of NRF2. This is demonstrated by decreased expression of inflammatory cytokine genes and a reduction in F4/80-stained liver macrophages. Notably, this anti-inflammatory effect is absent in Nrf2-knockout mice, confirming its NRF2-dependent mechanism of action., [Conclusions] P10 emerges as a promising NRF2 activator by selectively disrupting the β-TrCP1/NRF2 interaction, highlighting its potential as a therapeutic agent for diseases presenting acute liver inflammation., This research was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) (grants PDC2021-121421-I00, PDC2022-1337665-I00, PID2022-141786OB-I00, and PID2019-110061RB-I00). The Autonomous Community of Madrid (grants S2017BMD-3827 and P2022_BMD-7230). EC is the holder of an FPU contract of MIU (Ministry of Universities FPU2021, FPU21/02505)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

NRF2 activation by 6-MSITC increases the generation of neuroprotective, soluble α amyloid precursor protein by inducing the metalloprotease gene ADAM17

  • Carnicero-Senabre, Daniel
  • Jiménez-Villegas, José
  • Álvarez-Garrote, Sofía
  • Escoll, Maribel
  • Cuadrado, Antonio
  • Rojo, Ana I.
Better knowledge of the molecular actors governing sequential amyloid precursor protein (APP) proteolysis is crucial to endorse novel therapies aimed to delay Alzheimer's disease (AD) progression. ADAM17 (A Disintegrin and Metalloproteinase 17) is a type-I transmembrane protease involved in the non-amyloidogenic processing of APP that contributes to the maintenance of synaptic functions. In this work, we analyzed the 5′-flanking region and first intron of ADAM17 gene employing an in silico analysis. This strategy evidenced two regions which concentrate the binding sites of diverse transcription factor-families, including members of the b-ZIP small MAF, NRF2 and BACH1 proteins. Then, we found that the natural isothiocyanate 6-MSITC (6 methylsulfinyl hexyl isothiocyanate) increased both mRNA and protein levels of ADAM17 in an NRF2-dependent manner. In line, SH-SY5Y neurons released higher levels of the soluble APPα peptide as a result of ADAM17 activation. Overall, our study identifies inducible expression of ADAM17, and consequently protease activity, by NRF2., This research was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) (grants PID2019-110061RB-I00, PID-2021-122766OB-100 and PDC2021-121421-I00, PDC2022-133765-I00), CIBER -Consorcio Centro de Investigación Biomédica en Red-CB06/05/0010, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, and The Autonomous Community of Madrid (grant P2022/BMD-7230). DCS is a holder of an FPI contract of MICINN (Ministry of Science and Innovation, FPI-2020, PRE2020-091886). JJV is holder of a FPU contract of MIU (Ministry of Universities, FPU2020, FPU20/03326). This article is based upon work from COST Action CA20121, supported by COST (European Cooperation in Science and Technology) (www.cost.eu) (https://benbedphar.org/about-benbedphar/)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

NRF2 deficiency is associated with synaptic alterations and ether-linked phospholipid imbalance in the hippocampus

  • Carnicero-Senabre, Daniel
  • Barata, Mariana A.
  • Jiménez-Villegas, José
  • Guimas Almeida, Claudia
  • Cuadrado, Antonio
  • Rojo, Ana I.
Synaptic loss is a key factor in the cognitive decline observed during aging and in neurodegenerative diseases such as dementia, where synaptopathy plays a central role in hippocampal dysfunction. In this study, we investigated the role of NRF2, a master regulator of cellular homeostasis, in maintaining synaptic integrity. We assessed synaptic contacts both in vitro and in vivo and found that NRF2 deficiency leads to a significant reduction in vGLUT1 levels, accompanied by a decrease in the number of synaptic contacts. Because synapses are subject to highly dynamic membrane remodeling processes, we analyzed the lipid composition of hippocampi and synaptosomes from NRF2-deficient and wild-type mouse littermates. Our results revealed an accumulation of ether-linked phospholipids in NRF2-deficient mice. When primary neuronal and organotypic cultures were exposed to an ether-lipid precursor, synaptic density decreased. By contrast, the NRF2 activator 6-(methylsulfinyl)hexyl isothiocyanate (6-MSITC or hexaraphane) prevented synaptic loss. Although ether lipids are abundant components of neuronal membranes, their specific role in synaptic function and in age-related loss of homeostatic balance remains poorly understood. This study is the first to demonstrate that NRF2 plays an essential role in preserving synaptic homeostasis through lipid metabolism, suggesting its relevance in the context of aging and neurodegenerative diseases., This research was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) (grants PID2019-110061RB-I00, PID-2021-122766OB-100 and PDC2022-133765-I00), Ramón Areces Foundation (2024_Rojo), CIBER -Consorcio Centro de Investigación Biomédica en Red-CB06/05/0010, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, and The Autonomous Community of Madrid (grant P2022/BMD-7230). DCS holds an FPI contract of MICINN (Ministry of Science and Innovation, FPI-2020, PRE2020-091886). JJV holds an FPU PhD fellowship from the Spanish MIU (Ministry of Universities, FPU2020, FPU20/03326). This project has received funding (to CGA) from the Research Unit UID/04462: iNOVA4Health - Programa de Medicina Translacional and by the Associated Laboratory LS4FUTURE (LA/P/0087/2020), all financially supported by Fundação para a Ciência e Tecnologia (FCT)/Ministério da Educação, Ciência e Tecnologia and co‐funded by FEDER under the PT2020 Partnership Agreement); CGA holds CEEC/iNOVA4Health contract (FCT); and MB holds an FCT doctoral fellowship (10.54499/2020.06758. BD). This article is based upon work from COST Action CA20121, supported by COST (European Cooperation in Science and Technology) (www.cost.eu) (https://benbedphar.org/about-benbedphar/)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

An inhibitor of interaction between the transcription factor NRF2 and the E3 ubiquitin ligase adapter β-TrCP delivers anti-inflammatory responses in mouse liver

  • Fernández-Ginés, Raquel
  • Encinar, José Antonio
  • Hayes, John D.
  • Oliva Miguel, Baldomero
  • Rodríguez-Franco, Maria Isabel
  • Rojo, Ana I.
  • Cuadrado, Antonio
It is widely accepted that activating the transcription factor NRF2 will blast the physiological anti-inflammatory mechanisms, which will help combat pathologic inflammation. Much effort is being put in inhibiting the main NRF2 repressor, KEAP1, with either electrophilic small molecules or disrupters of the KEAP1/NRF2 interaction. However, targeting β-TrCP, the non-canonical repressor of NRF2, has not been considered yet. After in silico screening of ∼1 million compounds, we now describe a novel small molecule, PHAR, that selectively inhibits the interaction between β-TrCP and the phosphodegron in transcription factor NRF2. PHAR upregulates NRF2-target genes such as Hmox1, Nqo1, Gclc, Gclm and Aox1, in a KEAP1-independent, but β-TrCP dependent manner, breaks the β-TrCP/NRF2 interaction in the cell nucleus, and inhibits the β-TrCP-mediated in vitro ubiquitination of NRF2. PHAR attenuates hydrogen peroxide induced oxidative stress and, in lipopolysaccharide-treated macrophages, it downregulates the expression of inflammatory genes Il1b, Il6, Cox2, Nos2. In mice, PHAR selectively targets the liver and greatly attenuates LPS-induced liver inflammation as indicated by a reduction in the gene expression of the inflammatory cytokines Il1b, TNf, and Il6, and in F4/80-stained liver resident macrophages. Thus, PHAR offers a still unexplored alternative to current NRF2 activators by acting as a β-TrCP/NRF2 interaction inhibitor that may have a therapeutic value against undesirable inflammation., This research was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) (grants PID2019-110061RB-I00, PID2021-122650OB-I00, and PDC2021-121421-I00) and The Autonomous Community of Madrid (grant B2017/BMD-3827). RFG enjoyed FPI contract of MINECO (FPI-2017). The Spanish Ministry of Economy and Competitiveness (MINECO, Project RTI2018-096724-B-C21) and the Generalitat Valenciana (PROMETEO/2021/059) supported the work in the Encinar laboratory.